QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (67) Citing Articles via Google Scholar Google Scholar Articles by Pavelko, K. D. Articles by Rodriguez, M. Search for Related Content PubMed PubMed Citation Articles by Pavelko, K. D. Articles by Rodriguez, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB METHYLPREDNISOLONE TRITIUM

 Previous Article  |  Next Article 

The Journal of Neuroscience, April 1, 1998, 18(7):2498-2505

Acceleration in the Rate of CNS Remyelination in Lysolecithin-Induced Demyelination

Kevin D. Pavelko¹, Baziel G. M. van Engelen^{1, 2}, and Moses Rodriguez¹

¹ Departments of Neurology and Immunology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, and ² Institute of Neurology, University Hospital Nijmegen, 6500 HB Nijmegen, The Netherlands

One important therapeutic goal during CNS injury from trauma or demyelinating diseases such as multiple sclerosis is to develop methods to promote remyelination. We tested the hypothesis that spontaneous remyelination in the toxic nonimmune model of lysolecithin-induced demyelination can be enhanced by manipulating the inflammatory response. In PBS-treated SJL/J mice, the number of remyelinating axons per square millimeter of lesion area increased significantly 3 and 5 weeks after lysolecithin injection in the spinal cord. However, methylprednisolone or a monoclonal antibody (mAb), SCH94.03, developed for its ability to promote remyelination in the Theiler's virus murine model of demyelination, further increased the number of remyelinating axons per lesion area at 3 weeks by a factor of 2.6 and 1.9, respectively, but did not increase the ratio of myelin sheath thickness to axon diameter or the number of cells incorporating tritiated thymidine in the lesion. After 3 weeks, the number of remyelinating axons in the methylprednisolone or mAb SCH94.03 treatment groups was similar to the spontaneous remyelination in the 5 week PBS control-treated group, indicating that these treatments promoted remyelination by increasing its rate rather than its extent. To address a mechanism for promoting remyelination, through an effect on scavenger function, we assessed morphometrically the number of macrophages in lesions after methylprednisolone and mAb SCH94.03 treatment. Methylprednisolone reduced the number of macrophages, but SCH94.03 did not, although both enhanced remyelination. This study supports the hypothesis that even in toxic nonprimary immune demyelination, manipulating the inflammatory response is a benefit in myelin repair.

Key words: lysolecithin; CNS; injury; demyelination; remyelination; immunoglobulin; corticosteroids; autoantibodies

---

Copyright © 1998 Society for Neuroscience  0270-6474/98/1872498-08$05.00/0

This article has been cited by other articles:

				S. Chandran, D. Hunt, A. Joannides, C. Zhao, A. Compston, and R. J.M Franklin Myelin repair: the role of stem and precursor cells in multiple sclerosis Phil Trans R Soc B, January 12, 2008; 363(1489): 171 - 183. [Abstract] [Full Text] [PDF]

				C. Fonte, J. Grenier, A. Trousson, A. Chauchereau, O. Lahuna, E.-E. Baulieu, M. Schumacher, and C. Massaad Involvement of {beta}-catenin and unusual behavior of CBP and p300 in glucocorticosteroid signaling in Schwann cells PNAS, October 4, 2005; 102(40): 14260 - 14265. [Abstract] [Full Text] [PDF]

				I. Pirko and M. Rodriguez Pulsed Intravenous Methylprednisolone Therapy in Progressive Multiple Sclerosis: Need for a Controlled Trial Arch Neurol, July 1, 2004; 61(7): 1148 - 1149. [Full Text] [PDF]

				M Stangel and H-P Hartung Despair of repair J. Neurol. Neurosurg. Psychiatry, January 1, 2002; 72(1): 1 - 4. [Full Text] [PDF]

				R. Zivadinov, R. A. Rudick, R. De Masi, D. Nasuelli, M. Ukmar, R. S. Pozzi-Mucelli, A. Grop, G. Cazzato, and M. Zorzon Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS Neurology, October 9, 2001; 57(7): 1239 - 1247. [Abstract] [Full Text] [PDF]

				N D Richert, J L Ostuni, C N Bash, T P Leist, H F McFarland, and J A Frank Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis Multiple Sclerosis, February 1, 2001; 7(1): 49 - 58. [Abstract] [PDF]

				A. E. Warrington, K. Asakura, A. J. Bieber, B. Ciric, V. Van Keulen, S. V. Kaveri, R. A. Kyle, L. R. Pease, and M. Rodriguez Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis PNAS, June 6, 2000; 97(12): 6820 - 6825. [Abstract] [Full Text] [PDF]

				S Adler, J Martinez, D S Williams, and J G Verbalis Positive association between blood brain barrier disruption and osmotically-induced demyelination Multiple Sclerosis, February 1, 2000; 6(1): 24 - 31. [Abstract] [PDF]

				M. Stangel, K. V. Toyka, and R. Gold Mechanisms of High-Dose Intravenous Immunoglobulins in Demyelinating Diseases Arch Neurol, June 1, 1999; 56(6): 661 - 663. [Abstract] [Full Text] [PDF]

				R. J.M. Franklin Review : Remyelination--A Regenerative Process in the CNS Neuroscientist, May 1, 1999; 5(3): 184 - 191. [Abstract] [PDF]

				D. Mcgavern, K. Asakura, and M. Rodriquez Do Antibodies Stimulate Myelin Repair in Multiple Sclerosis? Neuroscientist, January 1, 1999; 5(1): 19 - 28. [Abstract] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help